28Jan 2021
Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer

Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer

Prostate‐specific membrane antigen (PSMA)‐targeted radionuclide therapy (TRT) has demonstrated efficacy and tolerability with a dose–response effect in phase I/II trials in men with metastatic castration‐resistant prostate cancer (mCRPC).

  • #urology

Like

Save

Share